Bank of New York Mellon Corp Boosts Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Bank of New York Mellon Corp boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 2.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 421,938 shares of the company’s stock after acquiring an additional 9,888 shares during the period. Bank of New York Mellon Corp owned 0.34% of Vaxcyte worth $34,540,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PCVX. Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after buying an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. raised its holdings in shares of Vaxcyte by 5.9% in the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after buying an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Vaxcyte by 47.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after buying an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Vaxcyte in the third quarter worth $41,114,000. Finally, Franklin Resources Inc. raised its holdings in shares of Vaxcyte by 13.2% in the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock worth $315,162,000 after buying an additional 324,560 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PCVX. Guggenheim reissued a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $147.50.

Vaxcyte Price Performance

NASDAQ PCVX opened at $71.18 on Friday. The company has a market capitalization of $9.17 billion, a price-to-earnings ratio of -15.47 and a beta of 1.02. The firm’s fifty day moving average price is $83.33 and its 200 day moving average price is $94.51. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Activity at Vaxcyte

In other news, CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $92.25, for a total transaction of $218,263.50. Following the completion of the sale, the chief executive officer now directly owns 136,215 shares in the company, valued at $12,565,833.75. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00. Following the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,720,610.98. This trade represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,616 shares of company stock worth $4,768,521 over the last 90 days. Company insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.